Total Nutraceutical Solutions (TNS) has started evaluating several proprietary mushroom compounds for activity in controlling the development of Alzheimer’s Disease (AD). Model Biosystems (MBS) has informed TNS that
Sanofi-aventis has reported financial results for the third-quarter of 2009. The company generated net sales of E7,400m, up 8% on a reported basis. Exchange rate movements had a
MAP Pharmaceuticals (MAP) has completed a planned interim safety review of the open-label, long-term safety extension of its phase 3 FREEDOM 301 clinical trial, with its Levadex orally
Market research firm, Mintel has reported that because of the outbreak of H1N1 (swine flu), people around the world are flocking to drugstores and supermarkets to stock up
Interleukin will fulfill and process all Inherent Health genetic tests through the company’s CLIA-certified laboratory in Waltham, Massachusetts. Amway Global will assist with marketing, implementation and technical operations
Bikam and Dalton Medicinal Chemistry (Dalton) have renewed their exclusive worldwide collaboration to discover and develop new ophthalmology therapeutics. As per the renewed agreement, Dalton will continue to
Shire has reported study results on INTUNIV (guanfacine) Extended Release Tablets. INTUNIV was recently approved by the FDA as the first nonscheduled alpha-2A agonist indicated for the treatment
Cumberland Pharmaceuticals (Cumberland) and Phebra have entered into an exclusive partnership for the commercialization of Caldolor (ibuprofen) Injection in Australia and New Zealand. Caldolor, an intravenous formulation of
Roche has released the results of a first phase III clinical study using Taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research. The
Ipsen has launched Dysport in the US for the treatment of cervical dystonia in adults. Dysport is the latest addition to the Ipsen’s drugs already available in North
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.